ArticleCell death & disease2026

ROR1-PI3K/AKT signaling drives adaptive resistance to cell cycle blockade in TP53 mutated ovarian cancer.

Juuli Raivola et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.